+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Neuroprotection Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017-2025

  • ID: 4851486
  • Report
  • March 2018
  • Region: Global
  • 197 pages
  • Transparency Market Research
1 of 2

Enquire about COVID-19 updates for this product.

Enquire Now

Global Neuroprotection Market: Overview

This report on the Neuroprotection market analyzes the current and future scenario of the global market. Increasing incidence of neurological disorders. Product development, drug launches and initiatives for increasing awareness about Neuroprotection are the major drivers of the global Neuroprotection Market.

The Neuroprotection market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on product type, application, and geography. A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the market overview section. In addition, the section comprises competitive matrix and company profiles with business overview to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis, by geography and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global Neuroprotection market.

Global Neuroprotection Market: Key Segments

Based on product type, the market has been segmented into Free Radical Trapping Agents (Antioxidants), Glutamate Antagonists (Anti-Excitotoxic Agents), Apoptosis Inhibitors, Anti-inflammatory Agents, Neurotrophic Factors (NTFs), Metal Ion Chelators, Stimulants, and Others. The application segments have been analyzed based on available approved products for prevention and treatment. The market size and forecast for each of these segments have been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year.

Global Neuroprotection Market: Regional Outlook

Geographically, the global Neuroprotection market has been categorized into five major regions and the key countries in the respective region: North America (the U.S., Canada), Europe (the U.K., Germany, France, Spain, Italy, Russia, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America) and Middle East & Africa (South Africa, GCC countries, Israel, and Rest of Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries have been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year. The research study also covers the competitive scenario in these regions.

Companies Mentioned in Report

The report also profiles major players in the global Neuroprotection market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. The major players in the Neuroprotection Market are, Daiichi Sankyo Company, Eli Lilly and Company, Allergan plc, Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Novartis AG, AstraZeneca plc, Astrocyte Pharmaceuticals, Inc., F. Hoffmann-La Roche AG, Biogen Inc., and other prominent players.

 The global Neuroprotection market is segmented as given below:

  • Global Neuroprotection Market Revenue, by Product Type, 2015–2025
    • Free Radical Trapping Agents (Antioxidants)
    • Glutamate Antagonists (Anti-Excitotoxic Agents)
    • Apoptosis Inhibitors
    • Anti-inflammatory Agents
    • Neurotrophic Factors (NTFs)
    • Metal Ion Chelators
    • Stimulants
    • Others
  • Global Neuroprotection Market Revenue, By Application, 2015-2025
    • Prevention
    • Treatment
  • Global Neuroprotection Market Revenue, By Geography, 2015–2025
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • France
      • U.K.
      • Spain
      • Italy
      • Russia
      • Rest of Europe
    • Asia Pacific
      • India
      • China
      • Japan
      • Australia & New Zealand
      • Rest of Asia Pacific
    • Latin America
      • Brazil
      • Mexico
      • Rest of Latin America
    • Middle East & Africa
      • GCC countries
      • South Africa
      • Israel
      • Rest of Middle East & Africa
Note: Product cover images may vary from those shown
2 of 2
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights

2. Assumptions and Research Methodology
2.1. Assumptions and Acronyms Used
2.2. Research Methodology

3. Executive Summary
3.1. Global Neuroprotection Market Size (US$ Mn) and Distribution, by Region, 2017 and 2025
3.2. Global Neuroprotection Market: Market Snapshot

4. Market Overview
4.1. Global Neuroprotection Market: Product Overview
4.2. Global Neuroprotection Market: Key Industry Developments

5. Market Dynamics
5.1. Drivers and Restraints Snapshot Analysis
5.2. Drivers
5.3. Restraints
5.4. Opportunities
5.5. Global Neuroprotection Market Outlook
5.6. Porters Five Forces
5.7. Pipeline Analysis
5.8. Mergers & Acquisition
5.9. Product mapping

6. Global Neuroprotection Market Analysis, by Product
6.1. Introduction
6.2. Key Insights
6.3. Global Neuroprotection Market Value Share Analysis, by Product
6.4. Global Neuroprotection Market Value (US$ Mn) Forecast , by Product
6.4.1. Free Radical Trapping Agents (Antioxidants)
6.4.2. Glutamate Antagonists (Anti-Excitotoxic Agents)
6.4.3. Apoptosis Inhibitors
6.4.4. Anti-inflammatory Agents
6.4.5. Neurotrophic Factors (NTFs)
6.4.6. Metal Ion Chelators
6.4.7. Stimulants
6.4.8. Others
6.5. Global Neuroprotection Market Attractiveness, by Product

7. Global Neuroprotection Market, By Application
7.1. Global Neuroprotection Market Value Share Analysis, by Application
7.2. Global Neuroprotection Market Value (US$ Mn) Forecast, by Application
7.2.1. Prevention
7.2.2. Treatment
7.3. Global Neuroprotection Market Attractiveness Analysis, by Application
7.3.1. Prevention
7.3.2. Treatment

8. Global Neuroprotection Market Analysis, by Region
8.1. Global Neuroprotection Market Forecast, by Region, 2015-2025
8.1.1. North America
8.1.2. Europe
8.1.3. Asia Pacific
8.1.4. Latin America
8.1.5. Middle East & Africa
8.2. Global Neuroprotection Market Value Share Analysis, by Region
8.3. Global Neuroprotection Market Attractiveness Analysis, by Region

9. North America Neuroprotection Market Analysis
9.1. North America Neuroprotection Market Key Findings
9.2. North America Neuroprotection Market Overview
9.3. North America Neuroprotection Market Value Share Analysis, by Product
9.3.1. Free Radical Trapping Agents (Antioxidants)
9.3.2. Glutamate Antagonists (Anti-Excitotoxic Agents)
9.3.3. Apoptosis Inhibitors
9.3.4. Anti-inflammatory Agents
9.3.5. Neurotrophic Factors (NTFs)
9.3.6. Metal Ion Chelators
9.3.7. Stimulants
9.3.8. Others
9.4. North America Neuroprotection Market Value Share Analysis, by Application
9.4.1. Prevention
9.4.2. Treatment
9.5. North America Neuroprotection Market Forecast, by Country
9.5.1. U.S.
9.5.2. Canada
9.6. North America Neuroprotection Market Attractiveness Analysis
9.6.1. By Product
9.6.2. By Application
9.6.3. By Country
9.7. Trends

10. Europe Neuroprotection Market Analysis
10.1. Europe Neuroprotection Market Key Findings
10.2. Europe Neuroprotection Market Overview
10.3. Europe Neuroprotection Market Value Share Analysis, by Product
10.3.1. Free Radical Trapping Agents (Antioxidants)
10.3.2. Glutamate Antagonists (Anti-Excitotoxic Agents)
10.3.3. Apoptosis Inhibitors
10.3.4. Anti-inflammatory Agents
10.3.5. Neurotrophic Factors (NTFs)
10.3.6. Metal Ion Chelators
10.3.7. Stimulants
10.3.8. Others
10.4. Europe Neuroprotection Market Value Share Analysis, by Application
10.4.1. Prevention
10.4.2. Treatment
10.5. Europe Neuroprotection Market Forecast, by Country
10.5.1. Germany
10.5.2. U.K.
10.5.3. France
10.5.4. Italy
10.5.5. Spain
10.5.6. Russia
10.5.7. Rest of Europe
10.6. Europe Neuroprotection Market Attractiveness Analysis
10.6.1. By Product
10.6.2. By Application
10.6.3. By Country
10.7. Trends

11. Asia Pacific Neuroprotection Market Analysis
11.1. Asia Pacific Neuroprotection Market Key Findings
11.2. Asia Pacific Neuroprotection Market Overview
11.3. Asia Pacific Neuroprotection Market Value Share Analysis, by Product
11.3.1. Free Radical Trapping Agents (Antioxidants)
11.3.2. Glutamate Antagonists (Anti-Excitotoxic Agents)
11.3.3. Apoptosis Inhibitors
11.3.4. Anti-inflammatory Agents
11.3.5. Neurotrophic Factors (NTFs)
11.3.6. Metal Ion Chelators
11.3.7. Stimulants
11.3.8. Others
11.4. Asia Pacific Neuroprotection Market Value Share Analysis, by Application
11.4.1. Prevention
11.4.2. Treatment
11.5. Asia Pacific Neuroprotection Market Forecast, by Country
11.5.1. China
11.5.2. India
11.5.3. Japan
11.5.4. Australia & New Zealand
11.6. Asia Pacific Neuroprotection Market Attractiveness Analysis
11.6.1. By Product
11.6.2. By Application
11.6.3. By Country
11.7. Trends

12. Latin America Neuroprotection Market Analysis
12.1. Latin America Neuroprotection Market Key Findings
12.2. Latin America Neuroprotection Market Overview
12.3. Latin America Neuroprotection Market Value Share Analysis, by Product
12.3.1. Free Radical Trapping Agents (Antioxidants)
12.3.2. Glutamate Antagonists (Anti-Excitotoxic Agents)
12.3.3. Apoptosis Inhibitors
12.3.4. Anti-inflammatory Agents
12.3.5. Neurotrophic Factors (NTFs)
12.3.6. Metal Ion Chelators
12.3.7. Stimulants
12.3.8. Others
12.4. Latin America Neuroprotection Market Value Share Analysis, by Application
12.4.1. Prevention
12.4.2. Treatment
12.5. Latin America Neuroprotection Market Forecast, by Country
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Rest of LATAM
12.6. Latin America Neuroprotection Market Attractiveness Analysis
12.6.1. By Product
12.6.2. By Application
12.6.3. By Country
12.7. Trends

13. MEA Neuroprotection Market Analysis
13.1. MEA Neuroprotection Market Key Findings
13.2. MEA Neuroprotection Market Overview
13.3. MEA Neuroprotection Market Value Share Analysis, by Product
13.3.1. Free Radical Trapping Agents (Antioxidants)
13.3.2. Glutamate Antagonists (Anti-Excitotoxic Agents)
13.3.3. Apoptosis Inhibitors
13.3.4. Anti-inflammatory Agents
13.3.5. Neurotrophic Factors (NTFs)
13.3.6. Metal Ion Chelators
13.3.7. Stimulants
13.3.8. Others
13.4. MEA Neuroprotection Market Value Share Analysis, by Application
13.4.1. Prevention
13.4.2. Treatment
13.5. MEA Neuroprotection Market Forecast, by Country
13.5.1. GCC Countries
13.5.2. South Africa
13.5.3. Israel
13.5.4. Rest of MEA
13.6. North America Neuroprotection Market Attractiveness Analysis
13.6.1. By Product
13.6.2. By Application
13.6.3. By Country
13.7. Trends

14. Competition Landscape
14.1. Global Neuroprotection Market Share Analysis, by Company (2016)
14.2. Company Profiles
14.2.1. Daiichi Sankyo Company
14.2.1.1. Overview (HQ, Employee Strength, Business Segments)
14.2.1.2. Financials
14.2.1.3. Recent Developments
14.2.1.4. Strategy
14.2.2. Eli Lilly and Company
14.2.2.1. Overview (HQ, Employee Strength, Business Segments)
14.2.2.2. Financials
14.2.2.3. Recent Developments
14.2.2.4. Strategy
14.2.3. Allergan plc.
14.2.3.1. Overview (HQ, Employee Strength, Business Segments)
14.2.3.2. Financials
14.2.3.3. Recent Developments
14.2.3.4. Strategy
14.2.4. Dr. Reddy’s Laboratories Ltd.
14.2.4.1. Overview (HQ, Employee Strength, Business Segments)
14.2.4.2. Financials
14.2.4.3. Recent Developments
14.2.4.4. Strategy
14.2.5. Teva Pharmaceutical Industries Ltd.
14.2.5.1. Overview (HQ, Employee Strength, Business Segments)
14.2.5.2. Financials
14.2.5.3. Recent Developments
14.2.5.4. Strategy
14.2.6. Novartis AG
14.2.6.1. Overview (HQ, Employee Strength, Business Segments)
14.2.6.2. Financials
14.2.6.3. Recent Developments
14.2.6.4. Strategy
14.2.7. AstraZeneca plc.
14.2.7.1. Overview (HQ, Employee Strength, Business Segments)
14.2.7.2. Financials
14.2.7.3. Recent Developments
14.2.7.4. Strategy
14.2.8. AstraZeneca plc.
14.2.8.1. Overview (HQ, Employee Strength, Business Segments)
14.2.8.2. Financials
14.2.8.3. Recent Developments
14.2.8.4. Strategy
14.2.9. Astrocyte Pharmaceuticals, Inc.
14.2.9.1. Overview (HQ, Employee Strength, Business Segments)
14.2.9.2. Financials
14.2.9.3. Recent Developments
14.2.9.4. Strategy
14.2.10. F. Hoffmann-La Roche AG
14.2.10.1. Overview (HQ, Employee Strength, Business Segments)
14.2.10.2. Financials
14.2.10.3. Recent Developments
14.2.10.4. Strategy
14.2.11. Biogen Inc.
14.2.11.1. Overview (HQ, Employee Strength, Business Segments)
14.2.11.2. Financials
14.2.11.3. Recent Developments
14.2.11.4. Strategy
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll